|Articles|July 5, 2023
New FDA Draft Guidance Shows That the Time for Decentralized Clinical Trials is Now.
Author(s)Science 37
On May 1, 2023, the U.S. Food and Drug Administration (FDA) released an updated Draft Guidance on decentralized trials. This release shows that the landscape of clinical research is rapidly evolving. The shift towards decentralized clinical trials presents an exciting opportunity for sponsors to improve patient engagement, enhance data quality, and accelerate clinical research. Are you prepared for what’s to come? Download the insight brief to learn more.
Trending on Applied Clinical Trials Online
1
Validity, Reliability, and Regulatory Considerations for Consumer Devices in Clinical Research Data Collection
2
ACT Brief: Real-Time Review Ecosystem Approach, AI Infrastructure Before Tools, and FDA Peptide Compounding Access
3
ACT Brief: ESG as Commercial Selection Factor, Real-Time Monitoring Scale Readiness, and FDA Cancer Trial Eligibility Expansion
4
FDA Finalizes Three Guidances to Broaden Cancer Clinical Trial Eligibility
5